The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta‐Analysis Study
Journal of Cosmetic Dermatology · 2025
DOI: 10.1111/jocd.70185 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Aditya K Gupta und 4 weiteren Autor:innen. Beteiligte Einrichtung: Mediprobe Research Inc., London, Ontario, Canada. Hauptthemen laut MEDLINE: Alopecia Areata, Janus Kinase Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Scant evidence exists for the relative efficacy of therapies for alopecia areata (AA)—including those approved by the Food and Drug Administration, namely, baricitinib, deuruxolitinib, and ritlecitinib.
Aims
We determined the relative efficacy and safety of monotherapy with janus kinase inhibitors (JAKIs), apremilast, and dupilumab.
Methods
Following a systematic review, we conducted Bayesian network meta‐analysis (NMAs) that produced Surface Under the Cumulative RAnking (SUCRA) values and point estimates for pairwise relative effects; we also performed sensitivity analyses.
Results
In total, regimens with eight various JAKIs were compared, namely, ruxolitinib, ATI‐501, baricitinib, brepocitinib, deuruxolitinib, ivarmacitinib, ritlecitinib, and tofacitinib. Our analyses ranked “deuruxolitinib 12 mg twice daily for 24 weeks,” the most efficacious insofar as “proportion of participants achieving SALT ≤ 20 at 24 weeks” (SALT 20 ) (SUCRA = 92.6%), and “proportion of participants achieving SALT ≤ 10 at 24 weeks” (SALT 10 ) (SUCRA = 97.7%). As per SALT 20 , the highest‐ranked regimen was more efficacious than “baricitinib 2 mg once daily for 24 weeks” (odds ratio [OR] = 5.37, 95% credible interval [CI] = 1.59, 13.70, p < 0.05). Furthermore, the efficacy of the FDA‐approved JAKIs exhibited a dose‐dependent relationship; for instance, baricitinib 4 mg once daily for 24 weeks was more efficacious than “baricitinib 2 mg once daily for 24 weeks” in terms of SALT 20 (OR = 2.25, 95% CI = 1.56, 3.21, p < 0.05). Results from our sensitivity analyses support that our base analyses were robust.
Conclusions
We produced high‐quality evidence on the comparative effectiveness of monotherapies for AA with various regimens of 8 JAKIs, including the FDA‐approved ones. Our findings can improve clinicians' decision‐making and update guidelines for medical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mediprobe Research Inc., London, Ontario, Canada.
- Division of Dermatology, Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Department of Dermatology, The Permanente Medical Group, Vallejo, California, USA.
- Department of Dermatology, University of California, San Francisco, San Francisco, California, USA.
- Department of Dermatology, Case Western Reserve University, Cleveland, Ohio, USA.
- Division of Dermatology, Women's College Hospital, Toronto, Ontario, Canada.
ORCID-Profile: Aditya K Gupta, Mesbah Talukder
Zitieren
APA
Gupta, A. K., Bamimore, M. A., Mirmirani, P., Piguet, V., & Talukder, M. (2025). The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta‐Analysis Study. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.70185
Vancouver
Gupta AK, Bamimore MA, Mirmirani P, Piguet V, Talukder M. The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta‐Analysis Study. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.70185
BibTeX
@article{Gupta2025,
author = {Gupta, Aditya K and Bamimore, Mary A and Mirmirani, Paradi and Piguet, Vincent and Talukder, Mesbah},
title = {The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta‐Analysis Study},
journal = {Journal of Cosmetic Dermatology},
year = {2025},
doi = {10.1111/jocd.70185}
}
EUVIMED